


AMENDMENTS TO CLAIMS


In the Claims:

Claim 1. (Currently Amended). A compound of the formula




including a pharmaceutically acceptable salt thereof wherein

x is 0 or 1,

R is H, alkyl or arylalkyl; alkenyl, aryl-(CH<sub>2</sub>)<sub>p</sub>, ~~heteroaryl-(CH<sub>2</sub>)<sub>p</sub>~~, cycloheteroalkyl-(CH<sub>2</sub>)<sub>p</sub>, or~~R can be joined together with the carbon to which it is attached to form a 3 to 7 membered ring which may optionally be fused to a benzene ring;~~~~R<sup>1</sup> is H or -COR<sup>2</sup> where R<sup>2</sup> is alkyl, aryl-(CH<sub>2</sub>)<sub>p</sub>, cycloheteroalkyl-(CH<sub>2</sub>)<sub>p</sub>, heteroaryl-(CH<sub>2</sub>)<sub>p</sub>, alkoxy or cycloalkyl-(CH<sub>2</sub>)<sub>p</sub>;~~~~p is 0 or an integer from 1 to 8; and~~~~A is a conformationally restricted dipeptide mimic which has the structure~~where Y is CH<sub>2</sub>,R<sup>7</sup>, R<sup>8</sup> and R<sup>9</sup> are independently selected from hydrogen, alkyl, alkenyl, cycloalkyl-(CH<sub>2</sub>)<sub>m</sub>, aryl-(CH<sub>2</sub>)<sub>m</sub> and heteroaryl-(CH<sub>2</sub>)<sub>m</sub>,

where m is 0 or an integer from 1 to 6;

R<sup>6</sup>, R<sup>10</sup>, R<sup>11</sup>, and R<sup>12</sup> are independently selected from hydrogen, alkyl, alkenyl, cycloalkyl-(CH<sub>2</sub>)<sub>p</sub>, aryl-(CH<sub>2</sub>)<sub>p</sub> and heteroaryl-(CH<sub>2</sub>)<sub>p</sub>; andR<sup>4</sup> is OH, alkyl, O-(CH<sub>2</sub>)<sub>p</sub>-heteroaryl,



R<sup>14</sup> is hydrogen, alkyl, cycloalkyl, or phenyl;

R<sup>15</sup> is hydrogen, alkyl, alkoxy or phenyl; and

R<sup>16</sup> is alkyl or aryl (CH<sub>2</sub>)<sub>m</sub>; wherein the term heteroaryl alone or as part of another group

refers to an aromatic ring which may optionally contain at most one sulfur atom or at most one oxygen atom and/or one to four nitrogen atoms, provided that the total number of heteroatoms in the ring is 4 or less, which aromatic ring may be optionally substituted with one, two or three substituents, and which aromatic ring may be fused to a benzene ring or a pyridyl ring to form a bicyclic ring which may be optionally substituted.


Claims 2-11. (Canceled).

Claim 12. (Previously Presented) A pharmaceutical composition comprising a compound as defined in Claim 1 and a pharmaceutically acceptable carrier therefor.

Claim 13. (Previously Presented) The pharmaceutical composition as defined in Claim 12 useful in the treatment of hypertension and/or congestive heart failure.

Claim 14. (Previously Presented) A method of treating hypertension and/or congestive heart failure, which comprises administering to a mammalian species a therapeutically effective amount of a composition as defined in Claim 12.

Claim 15. (Previously Presented) The compound as defined in Claim 1 which is



or a pharmaceutically acceptable salt thereof.